CONNECT WITH US
HealthTech

HealthTech

Dren Bio raises $350M to get blood cancer drug onto market in 2027

Endpoints News logo

Published on

Add as a preferred source on Google
Dren Bio raises $350M to get blood cancer drug onto market in 2027

Ex­clu­sive: Dren Bio nabs $350M for po­ten­tial 2027 launch of blood can­cer drug

Dren Bio has raised $350 mil­lion, hop­ing to get its lead blood can­cer drug on­to the mar­ket by the end of 2027, the Cal­i­for­nia drug …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Pathos rais­es $237M at $3B val­u­a­tion, signs Bris­tol My­ers neu­ro part­ner­ship October 23, 2026

Drug chem­istry CRO emerges from stealth, found­ed by ex-Ope­nAI sci­ence chief and tech vet­er­ans October 23, 2026

Cit­ing 'safe­ty' and 'free­dom,' HHS will al­low com­pound­ing of cer­tain well­ness pep­tides

An­throp­ic's lat­est biotech buy is a one-man stealth start­up run by a pseu­do­ny­mous Twit­ter poster



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.